#USA #New York #Securities Fraud #Pomerantz Law Firm #Ardelyx

Pomerantz Law Firm Files Class Action Against Ardelyx, Inc.

The Pomerantz Law Firm has officially initiated a class action lawsuit against Ardelyx, Inc., a pharmaceutical company traded on NASDAQ under the ticker ARDX. This significant legal development arises from allegations concerning potential securities fraud and questionable business practices within the company. Investors who have incurred losses are strongly encouraged to participate in the class action, ensuring their rights are protected through legal representation.

The law firm advises affected investors to reach out to them as soon as possible. A representative, Danielle Peyton, can be contacted via email at [email protected] or by phone at 646-581-9980. Furthermore, those interested in joining the lawsuit are urged to provide their contact information and details regarding their investment, including the number of shares purchased.

This class action primarily revolves around claims that Ardelyx and some of its executives may have engaged in fraudulent activities, thereby misleading investors regarding the company’s performance and prospects. Specifically, the claims stem from a press release issued by Ardelyx on August 6, 2026, where the company disclosed a downward revision in its revenue guidance for its IBSRELA product. The company cited increased payer utilization-management processes that limited patient access as a significant factor contributing to this downward adjustment.

Moreover, Ardelyx also announced the withdrawal of its revenue guidance for another product, XPHOZAH, pointing to